BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 25-Oct-2020

The Board of Directors has recommended 47% cash and 5% stock dividend for the year ended on June 30, 2020. The Board has also approved Tk. 250.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 15.12.2020, Time: 10:00 AM, Venue: Digital Platform. Record Date: 22.11.2020. (cont.1)

SQURPHARMA 12-Oct-2020

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 22, 2020 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.

SQURPHARMA 09-Jun-2020

(Q3 Un-audited): Consolidated EPS was Tk. 4.28 for January-March 2020 as against Tk. 3.69 for January-March 2019; Consolidated EPS was Tk. 12.44 for July 2019-March 2020 as against Tk. 11.15 for July 2018-March 2019. Consolidated NOCFPS was Tk. 10.13 for July 2019-March 2020 as against Tk. 10.57 for July 2018-March 2019. Consolidated NAV per share was Tk. 88.19 as on March 31, 2020 and Tk. 80.40 as on June 30, 2019.

SQURPHARMA 01-Jun-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on June 08, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2020.

SQURPHARMA 24-Mar-2020

The Company has informed that the Board of Directors has approved agreements with M/s Renata Oncology Ltd. and M/s Apex Pharma Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of the Company to meet increased demand of existing products and to introduce new products.

SQURPHARMA 27-Feb-2020

Mr. Anjan Chowdhury, one of the Directors of the Company, has further reported that he has completed his buying of 3,00,000 shares of the Company at prevailing market price through Stock Exchanges (DSE & CSE) as per declaration disseminated on 21.01.2020.

SQURPHARMA 27-Feb-2020

Mrs. Ratna Patra, one of the Directors of the Company, has further reported that she has completed her buying of 3,00,000 shares of the Company at prevailing market price through Stock Exchanges (DSE & CSE) as per declaration disseminated on 21.01.2020.

SQURPHARMA 23-Feb-2020

Mr. Tapan Chowdhury, one of the Directors of the Company, has further reported that he has completed his buying of 3,00,000 shares of the Company at prevailing market price through Stock Exchanges (DSE & CSE) as per declaration disseminated on 16.01.2020.

SQURPHARMA 23-Feb-2020

Samuel S Chowdhury, one of the Directors of the Company, has further reported that he has completed his buying of 3,00,000 shares of the Company at prevailing market price through Stock Exchanges (DSE & CSE) as per declaration disseminated on 16.01.2020.

SQURPHARMA 18-Feb-2020

(Continuation news of SQURPHARMA): ii) Initial estimated total cost will be Tk. 350.00 crore and to be financed by internally generated funds by the Square Pharmaceuticals Ltd. /Sponsors of Square Lifesciences Ltd. and iii) It is expected that the project would be completed by June, 2023. (end)

Previous Next page